Clinical Trials Using Cabozantinib S-malate

Clinical trials are research studies that involve people. The clinical trials on this list are studying Cabozantinib S-malate. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 26-34 of 34

  • Cabozantinib with Radiation Therapy for the Treatment of Sarcomas of the Extremities

    This phase I / II trial studies the side effects and best dose of cabozantinib when given with radiation therapy and how well it works in treating patients with sarcoma of the extremities. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving cabozantinib with radiation therapy may make the tumors smaller and reduce the amount of normal tissue that needs to be removed.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • Cabozantinib in Treating Patients with Locally Advanced Non-metastatic Kidney Cancer

    This phase II trial studies how well cabozantinib works in treating patients with kidney cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) and not to other places in the body (non-metastatic). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This study is being done to see if cabozantinib is effective in kidney cancer before surgery.
    Location: Emory University Hospital / Winship Cancer Institute, Atlanta, Georgia

  • Immediate Prostatectomy versus Cabozantinib Followed by Prostatectomy in Patients with Intermediate-High or High-Risk Prostate Cancer, The SPARC Study

    This phase II trial studies different biomarkers to gain a better understanding of how cabozantinib affects prostate cancer and the immune system in patients with intermediate-high or high-risk prostate cancer undergoing radical prostatectomy. Radical prostatectomy is a surgical procedure to remove the entire prostate and some of the tissue surrounding it. A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Biomarkers, obtained from blood and prostate tissue, include proteins (building blocks of the body, cells, and organs) involved in tumor growth and immune system activation, as well as genetic changes. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The purpose of this study is to determine the effect that cabozantinib has on these biomarkers and prostate cancer by comparing prostatectomy tissue and blood samples from patients who received cabozantinib to those who did not receive cabozantinib prior to prostatectomy. This study will also evaluate the safety and efficacy of cabozantinib in subjects with prostate cancer who are undergoing prostatectomy.
    Location: Duke University Medical Center, Durham, North Carolina

  • Cabozantinib and Pembrolizumab for the Treatment of Stage IIIC-IV Melanoma

    This phase I / II trial studies the best dose of cabozantinib when given together with pembrolizumab and to see how well it works in treating patients with stage IIIC-IV melanoma. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib and pembrolizumab may work better in treating patients with melanoma compared to pembrolizumab alone.
    Location: University of Iowa / Holden Comprehensive Cancer Center, Iowa City, Iowa

  • Cabozantinib and Durvalumab in Treating Patients with Stage III-IV Gastroesophageal Cancer and Other Gastrointestinal Malignancies

    This phase I / II trial studies the side effects and best dose of cabozantinib when given together with durvalumab in treating patients with stage III-IV gastroesophageal cancer and other gastrointestinal malignancies. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib and durvalumab may work better in treating patients with gastroesophageal cancer and other gastrointestinal malignancies compared to cabozantinib or durvalumab alone.
    Location: University of Kansas Cancer Center, Kansas City, Kansas

  • Cabozantinib S-malate and Avelumab in Treating Participants with Metastatic Kidney Cancer

    This phase I trial studies the side effects and best dose of cabozantinib s-malate and avelumab in treating participants with kidney cancer that has spread to other places in the body. Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib s-malate and avelumab may work better in treating participants with metastatic kidney cancer.
    Location: Huntsman Cancer Institute / University of Utah, Salt Lake City, Utah

  • Cabozantinib S-malate in Treating Children with Recurrent or Refractory High Grade Glioma

    This phase II trial studies the side effects and how well cabozantinib S-malate works in treating children with high grade glioma that has come back (recurrent) or does not respond to treatment (refractory). Cabozantinib S-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Riley Hospital for Children, Indianapolis, Indiana

  • Cabozantinib S-malate in Treating Patients with Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery

    This pilot phase II trial studies how well cabozantinib s-malate works in treating patients with pheochromocytomas or paragangliomas that have spread from the primary site to other places in the body (metastatic) and cannot be removed by surgery (unresectable). Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking the growth of new blood vessels necessary for tumor growth.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Cabozantinib S-malate and Nivolumab in Treating Patients with Advanced, Recurrent, or Metastatic Endometrial Cancer

    This randomized phase II trial studies how well cabozantinib s-malate and nivolumab work in treating patients with endometrial that has come back (recurrent) or spread to other places in the body (advanced or metastatic). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib and nivolumab may work better in treating endometrial cancer.
    Location: 29 locations